PT3383385T - Regimes de dosagem de melflufeno para o cancro - Google Patents

Regimes de dosagem de melflufeno para o cancro

Info

Publication number
PT3383385T
PT3383385T PT168057925T PT16805792T PT3383385T PT 3383385 T PT3383385 T PT 3383385T PT 168057925 T PT168057925 T PT 168057925T PT 16805792 T PT16805792 T PT 16805792T PT 3383385 T PT3383385 T PT 3383385T
Authority
PT
Portugal
Prior art keywords
cancer
dosage regimens
melflufen
melflufen dosage
regimens
Prior art date
Application number
PT168057925T
Other languages
English (en)
Original Assignee
Oncopeptides Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55177548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3383385(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncopeptides Ab filed Critical Oncopeptides Ab
Publication of PT3383385T publication Critical patent/PT3383385T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PT168057925T 2015-12-01 2016-12-01 Regimes de dosagem de melflufeno para o cancro PT3383385T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1521217.8A GB201521217D0 (en) 2015-12-01 2015-12-01 Dosage regimens

Publications (1)

Publication Number Publication Date
PT3383385T true PT3383385T (pt) 2020-10-26

Family

ID=55177548

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168057925T PT3383385T (pt) 2015-12-01 2016-12-01 Regimes de dosagem de melflufeno para o cancro

Country Status (26)

Country Link
US (2) US20180369141A1 (pt)
EP (3) EP3903777A1 (pt)
JP (2) JP6878431B2 (pt)
KR (2) KR102279629B1 (pt)
CN (1) CN108289876A (pt)
AU (2) AU2016363591B2 (pt)
BR (1) BR112018010012A8 (pt)
CA (1) CA3003102C (pt)
CY (1) CY1123469T1 (pt)
DK (1) DK3383385T4 (pt)
ES (1) ES2828033T5 (pt)
FI (1) FI3383385T4 (pt)
GB (1) GB201521217D0 (pt)
HR (1) HRP20201632T4 (pt)
HU (1) HUE051525T2 (pt)
IL (2) IL301019A (pt)
LT (1) LT3383385T (pt)
MX (2) MX2018006706A (pt)
PL (1) PL3383385T5 (pt)
PT (1) PT3383385T (pt)
RS (1) RS60986B2 (pt)
RU (2) RU2020134307A (pt)
SG (1) SG11201803551YA (pt)
SI (1) SI3383385T2 (pt)
WO (1) WO2017093443A1 (pt)
ZA (1) ZA201802816B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202103726RA (en) * 2018-10-18 2021-05-28 Oncopeptides Ab Compounds containing deuterium
CN114025753A (zh) * 2019-04-03 2022-02-08 肿瘤多肽有限公司 用美氟芬治疗al淀粉样变性
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) * 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
SE544998C2 (en) * 2021-01-13 2023-02-21 Bkmdcl Ab Peptide conjugates of melphalan for the treatment of cancer
WO2023281007A1 (en) * 2021-07-08 2023-01-12 Oncopeptides Ab Melflufen for use in the treatment of multiple myeloma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) * 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
PT3656393T (pt) * 2011-04-28 2022-11-03 Oncopeptides Ab Preparação liofilizada de dipéptidos citotóxicos
CN104756034B (zh) 2012-10-22 2017-06-23 派克·汉尼汾制造瑞典公司 操纵杆
CA2889753C (en) * 2012-10-26 2021-03-02 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
MX2015014097A (es) * 2013-04-08 2016-06-07 Berg Llc Tratamiento de cancer empleando terapias combinadas de coenzima q10.

Also Published As

Publication number Publication date
RU2020134307A (ru) 2020-11-27
EP3383385B1 (en) 2020-07-29
AU2016363591A1 (en) 2018-06-28
JP6878431B2 (ja) 2021-05-26
GB201521217D0 (en) 2016-01-13
IL301019A (en) 2023-05-01
KR102279629B1 (ko) 2021-07-20
NZ742548A (en) 2023-10-27
IL259101A (en) 2018-06-28
AU2016363591B2 (en) 2020-12-10
CY1123469T1 (el) 2022-03-24
DK3383385T3 (da) 2020-10-12
SI3383385T2 (sl) 2024-01-31
ZA201802816B (en) 2021-07-28
JP2021088560A (ja) 2021-06-10
US20180369141A1 (en) 2018-12-27
SI3383385T1 (sl) 2020-11-30
RS60986B1 (sr) 2020-11-30
BR112018010012A8 (pt) 2019-02-26
HRP20201632T4 (hr) 2023-11-10
EP3903777A1 (en) 2021-11-03
MX2018006706A (es) 2018-08-01
HRP20201632T1 (hr) 2021-01-08
RU2018123718A3 (pt) 2020-04-02
BR112018010012A2 (pt) 2018-11-21
ES2828033T5 (es) 2024-04-04
KR20180087254A (ko) 2018-08-01
AU2021200436A1 (en) 2021-02-25
JP2019501881A (ja) 2019-01-24
CA3003102C (en) 2022-09-13
EP3750534A1 (en) 2020-12-16
RU2734930C2 (ru) 2020-10-26
KR20210092327A (ko) 2021-07-23
EP3383385B2 (en) 2023-09-06
MX2021008738A (es) 2021-08-24
US20220047507A1 (en) 2022-02-17
CA3003102A1 (en) 2017-06-08
HUE051525T2 (hu) 2021-03-01
CN108289876A (zh) 2018-07-17
FI3383385T4 (fi) 2023-11-01
EP3383385A1 (en) 2018-10-10
WO2017093443A1 (en) 2017-06-08
DK3383385T4 (da) 2023-11-06
SG11201803551YA (en) 2018-05-30
LT3383385T (lt) 2020-12-28
PL3383385T5 (pl) 2023-12-18
PL3383385T3 (pl) 2021-05-04
RS60986B2 (sr) 2023-12-29
ES2828033T3 (es) 2021-05-25
RU2018123718A (ru) 2020-01-09

Similar Documents

Publication Publication Date Title
IL254705A0 (en) Combination therapy for cancer
ZA201702382B (en) Combination therapy for cancer
IL249231A0 (en) Pharmaceutical combinations for cancer treatment
HK1231381A1 (zh) 癌症組合療法
SI3347054T1 (sl) Režimi doziranja konjugatov zdravil proti TF protitelesu
IL259101A (en) Dosing regimens of malafone for cancer
IL246761A0 (en) Combined cancer treatment
HK1254687A1 (zh) 用於癌症的聯合療法
HRP20210383T8 (hr) Kombinirana terapija za rak
GB201521216D0 (en) Dosage regimen
GB201517643D0 (en) Dosage form for melatonin
GB201417819D0 (en) Agents for cancer therapy